Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation

Nelli Bejanyan, Claudio G Brunstein, Qing Cao, Aleksandr Lazaryan, Celalettin Ustun, Erica D Warlick, Mukta Arora, John E Wagner, Daniel J. Weisdorf

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Allogeneic hematologic cell transplantation (alloHCT) is the only curative therapy for many adults with hematological malignancies. However, it can be associated with substantial risks of morbidity and mortality that are dependent on patient comorbidity- or disease risk-related factors. Several pretransplantation prognostic scoring systems have been developed to estimate survival of patients undergoing alloHCT; however, there is significant interstudy variability in the predictive capacity of these assessment tools. We tested the prognostic capability of a composite scoring system including the disease risk index and HCT comorbidity index (DRCI). The DRCI scoring system was applied pretransplantation to determine whether it predicted clinical outcomes of 959 adult patients with hematological malignancies undergoing alloHCT from 2000 to 2013 at the University of Minnesota. The DRCI score categorized patients into 6 risk groups, with 2-year overall survival ranging between 74% for the very low-risk DRCI group and 34% for the very high-risk DRCI group. In multiple regression analyses adjusted for patient age and donor type, the risk of overall mortality independently increased as the DRCI score increased. Additionally, the DRCI score independently predicted risk of relapse, disease-free survival, and graft-versus-host disease-free/relapse-free survival. Our data demonstrate that the pretransplantation DRCI scoring system predicts outcomes after alloHCT and can be used to guide clinical decision making for patients considering alloHCT.

Original languageEnglish (US)
Pages (from-to)230-236
Number of pages7
JournalBlood Advances
Volume3
Issue number3
DOIs
StatePublished - Feb 12 2019

Fingerprint

Homologous Transplantation
Comorbidity
Survival
Cell Transplantation
Hematologic Neoplasms
Recurrence
Mortality
Graft vs Host Disease
Disease-Free Survival

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

Cite this

@article{6a79ed60253649b68e3e13f56b6b5332,
title = "Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation",
abstract = "Allogeneic hematologic cell transplantation (alloHCT) is the only curative therapy for many adults with hematological malignancies. However, it can be associated with substantial risks of morbidity and mortality that are dependent on patient comorbidity- or disease risk-related factors. Several pretransplantation prognostic scoring systems have been developed to estimate survival of patients undergoing alloHCT; however, there is significant interstudy variability in the predictive capacity of these assessment tools. We tested the prognostic capability of a composite scoring system including the disease risk index and HCT comorbidity index (DRCI). The DRCI scoring system was applied pretransplantation to determine whether it predicted clinical outcomes of 959 adult patients with hematological malignancies undergoing alloHCT from 2000 to 2013 at the University of Minnesota. The DRCI score categorized patients into 6 risk groups, with 2-year overall survival ranging between 74{\%} for the very low-risk DRCI group and 34{\%} for the very high-risk DRCI group. In multiple regression analyses adjusted for patient age and donor type, the risk of overall mortality independently increased as the DRCI score increased. Additionally, the DRCI score independently predicted risk of relapse, disease-free survival, and graft-versus-host disease-free/relapse-free survival. Our data demonstrate that the pretransplantation DRCI scoring system predicts outcomes after alloHCT and can be used to guide clinical decision making for patients considering alloHCT.",
author = "Nelli Bejanyan and Brunstein, {Claudio G} and Qing Cao and Aleksandr Lazaryan and Celalettin Ustun and Warlick, {Erica D} and Mukta Arora and Wagner, {John E} and Weisdorf, {Daniel J.}",
year = "2019",
month = "2",
day = "12",
doi = "10.1182/bloodadvances.2018018549",
language = "English (US)",
volume = "3",
pages = "230--236",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation

AU - Bejanyan, Nelli

AU - Brunstein, Claudio G

AU - Cao, Qing

AU - Lazaryan, Aleksandr

AU - Ustun, Celalettin

AU - Warlick, Erica D

AU - Arora, Mukta

AU - Wagner, John E

AU - Weisdorf, Daniel J.

PY - 2019/2/12

Y1 - 2019/2/12

N2 - Allogeneic hematologic cell transplantation (alloHCT) is the only curative therapy for many adults with hematological malignancies. However, it can be associated with substantial risks of morbidity and mortality that are dependent on patient comorbidity- or disease risk-related factors. Several pretransplantation prognostic scoring systems have been developed to estimate survival of patients undergoing alloHCT; however, there is significant interstudy variability in the predictive capacity of these assessment tools. We tested the prognostic capability of a composite scoring system including the disease risk index and HCT comorbidity index (DRCI). The DRCI scoring system was applied pretransplantation to determine whether it predicted clinical outcomes of 959 adult patients with hematological malignancies undergoing alloHCT from 2000 to 2013 at the University of Minnesota. The DRCI score categorized patients into 6 risk groups, with 2-year overall survival ranging between 74% for the very low-risk DRCI group and 34% for the very high-risk DRCI group. In multiple regression analyses adjusted for patient age and donor type, the risk of overall mortality independently increased as the DRCI score increased. Additionally, the DRCI score independently predicted risk of relapse, disease-free survival, and graft-versus-host disease-free/relapse-free survival. Our data demonstrate that the pretransplantation DRCI scoring system predicts outcomes after alloHCT and can be used to guide clinical decision making for patients considering alloHCT.

AB - Allogeneic hematologic cell transplantation (alloHCT) is the only curative therapy for many adults with hematological malignancies. However, it can be associated with substantial risks of morbidity and mortality that are dependent on patient comorbidity- or disease risk-related factors. Several pretransplantation prognostic scoring systems have been developed to estimate survival of patients undergoing alloHCT; however, there is significant interstudy variability in the predictive capacity of these assessment tools. We tested the prognostic capability of a composite scoring system including the disease risk index and HCT comorbidity index (DRCI). The DRCI scoring system was applied pretransplantation to determine whether it predicted clinical outcomes of 959 adult patients with hematological malignancies undergoing alloHCT from 2000 to 2013 at the University of Minnesota. The DRCI score categorized patients into 6 risk groups, with 2-year overall survival ranging between 74% for the very low-risk DRCI group and 34% for the very high-risk DRCI group. In multiple regression analyses adjusted for patient age and donor type, the risk of overall mortality independently increased as the DRCI score increased. Additionally, the DRCI score independently predicted risk of relapse, disease-free survival, and graft-versus-host disease-free/relapse-free survival. Our data demonstrate that the pretransplantation DRCI scoring system predicts outcomes after alloHCT and can be used to guide clinical decision making for patients considering alloHCT.

UR - http://www.scopus.com/inward/record.url?scp=85060399684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060399684&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2018018549

DO - 10.1182/bloodadvances.2018018549

M3 - Article

C2 - 30674457

AN - SCOPUS:85060399684

VL - 3

SP - 230

EP - 236

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 3

ER -